Role of colorectal cancer stem cells in resistance to apoptosis and treatment in colorectal cancer

Safa, Ahmad R.

doi:10.1016/b978-0-12-819937-4.00003-0

Cited by 1 publication

(1 citation statement)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanisms that contribute to drug resistance include the mutations of drug targets, the inactivation of apoptotic pathways, enhanced DNA damage repair and alterations in drug metabolism [ 16 ]. The major contributors to drug resistance in CRC are cancer stem cells (CSC), a rare subpopulation of cancer cells endowed with self-renewal properties, unlimited cell division capability and differentiation potential [ 17 ]. The combined administration of agents with non-overlapping mechanisms of action and/or different cell targets and/or synergistic effects may be an encouraging strategy to increase treatment efficacy and to reduce the side effects associated with conventional treatments (i.e., neutropenia, diarrhea and gastro-, neuro- and nephro-toxicity, among others).…”

Section: Pathogenesis and Clinical Management Of Colorectal Cancermentioning

confidence: 99%

Dietary Polyphenols: Promising Adjuvants for Colorectal Cancer Therapies

Bracci

Fabbri

Cornò

et al. 2021

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a major cancer type and a leading cause of death worldwide. Despite advances in therapeutic management, the current medical treatments are not sufficient to control metastatic disease. Treatment-related adverse effects and drug resistance strongly contribute to therapy failure and tumor recurrence. Combination therapy, involving cytotoxic treatments and non-toxic natural compounds, is arousing great interest as a promising more effective and safer alternative. Polyphenols, a heterogeneous group of bioactive dietary compounds mainly found in fruit and vegetables, have received great attention for their capacity to modulate various molecular pathways active in cancer cells and to affect host anticancer response. This review provides a summary of the most recent (i.e., since 2016) preclinical and clinical studies using polyphenols as adjuvants for CRC therapies. These studies highlight the beneficial effects of dietary polyphenols in combination with cytotoxic drugs or irradiation on both therapy outcome and drug resistance. Despite substantial preclinical evidence, data from a few pilot clinical trials are available to date with promising but still inconclusive results. Larger randomized controlled studies and polyphenol formulations with improved bioavailability are needed to translate the research progress into clinical applications and definitively prove the added value of these molecules in CRC management.

show abstract

Section: Pathogenesis and Clinical Management Of Colorectal Cancermentioning

confidence: 99%